A third of the radiotracer dose: two decades of progress in pediatric [ 18 F]fluorodeoxyglucose PET/CT and PET/MR imaging.

Autor: Waelti S; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland.; Department of Radiology and Nuclear Medicine, Children's Hospital of Eastern Switzerland, St. Gallen, Switzerland., Skawran S; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Sartoretti T; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Schwyzer M; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Gennari AG; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Mader C; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Treyer V; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Kellenberger CJ; University of Zurich, Zurich, Switzerland.; Department of Diagnostic Imaging, University Children's Hospital Zurich, Zurich, Switzerland., Burger IA; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland.; Department of Nuclear Medicine, Kantonsspital Baden, Baden, Switzerland., Hany T; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland.; MRI Bahnhofplatz, Zurich, Switzerland., Maurer A; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Huellner MW; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland.; University of Zurich, Zurich, Switzerland., Messerli M; Department of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, CH-8091, Zurich, Switzerland. michael.messerli@usz.ch.; University of Zurich, Zurich, Switzerland. michael.messerli@usz.ch.
Jazyk: angličtina
Zdroj: European radiology [Eur Radiol] 2024 May; Vol. 34 (5), pp. 3252-3259. Date of Electronic Publication: 2023 Oct 19.
DOI: 10.1007/s00330-023-10319-6
Abstrakt: Objectives: To assess the evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between years 2000 and 2021.
Methods: Pediatric patients (≤ 16 years) referred for 18F-FDG PET/CT or PET/MR imaging of the body during 2000 and 2021 were retrospectively included. The amount of administered radiotracer activity in megabecquerel (MBq) was recorded, and signal-to-noise ratio (SNR) was measured in the right liver lobe with a 4 cm 3 volume of interest as an indicator for objective image quality. Descriptive statistics were computed.
Results: Two hundred forty-three children and adolescents underwent a total of 466 examinations. The median injected 18F-FDG activity in MBq decreased significantly from 296 MBq in 2000-2005 to 100 MBq in 2016-2021 (p < 0.001), equaling approximately one-third of the initial amount. The median SNR ratio was stable during all years with 11.7 (interquartile range [IQR] 10.7-12.9, p = 0.133).
Conclusions: Children have benefited from a massive reduction in the administered 18F-FDG dose over the past 20 years without compromising objective image quality.
Clinical Relevance Statement: Radiotracer dose was reduced considerably over the past two decades of pediatric F-18-fluorodeoxyglucose PET/CT and PET/MR imaging highlighting the success of technical innovations in pediatric PET imaging.
Key Points: • The evolution of administered radiotracer activity for F-18-fluorodeoxyglucose (18F-FDG) PET/CT or PET/MR in pediatric patients (0-16 years) between 2000 and 2021 was assessed. • The injected tracer activity decreased by 66% during the study period from 296 megabecquerel (MBq) to 100 MBq (p < 0.001). • The continuous implementation of technical innovations in pediatric hybrid 18F-FDG PET has led to a steady decrease in the amount of applied radiotracer, which is particularly beneficial for children who are more sensitive to radiation.
(© 2023. The Author(s).)
Databáze: MEDLINE
Externí odkaz: